Semaglutide for Beginners: GLP-1 and Appetite Control
A clinician I spoke with mentioned that many patients ask about semaglutide after reading news headlines, yet few understand how the compound actually works. Semaglutide belongs to a class of molecules known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. These agents were initially studied for type 2 diabetes management, but weight loss emerged as a consistent finding in trials. In a 2021 paper published in the New England Journal of Medicine, Wilding and colleagues reported that once-weekly semaglutide 2.4 mg led to a mean body weight reduction of 14.9 percent over 68 weeks in adults with obesity. That result placed semaglutide among the most effective pharmaceutical interventions for weight management studied to date.
Understanding semaglutide requires a basic grasp of the GLP-1 system. GLP-1 is an incretin hormone secreted by intestinal L-cells after food intake. It signals the pancreas to release insulin, suppresses glucagon, and slows gastric emptying. In the brain, GLP-1 receptors are densely expressed in the hypothalamus and brainstem, regions that regulate appetite and satiety. Semaglutide is a synthetic analogue of human GLP-1 with structural modifications that extend its half-life to approximately one week. That long duration allows for once-weekly subcutaneous administration, a practical advantage over earlier GLP-1 RAs that required daily or twice-daily dosing.
How GLP-1 receptor activation changes feeding behaviour
Research on GLP-1 receptor activation has focused on both peripheral and central mechanisms. Peripherally, delayed gastric emptying means food remains in the stomach longer, which contributes to feelings of fullness. Centrally, GLP-1 receptor agonists act on the arcuate nucleus of the hypothalamus, reducing activity in neurons that promote hunger and increasing activity in neurons that promote satiety. A 2019 functional MRI study by van Bloemendaal and colleagues in Diabetes Care showed that GLP-1 receptor activation blunted brain responses to food images in areas linked to reward and motivation. That finding suggests semaglutide may reduce the appeal of highly palatable foods, not just the physical drive to eat.
Animal studies have further clarified the dose-response relationship. In a 2020 paper published in Molecular Metabolism, Gabery and colleagues demonstrated that semaglutide accumulates in brainstem regions including the area postrema and nucleus tractus solitarius. Those regions are known to mediate nausea and conditioned taste aversion, which may explain why gastrointestinal side effects are common with semaglutide. The same study found that weight loss occurred even when food intake was not dramatically reduced, implying that semaglutide may increase energy expenditure or alter nutrient partitioning. However, those effects have not been consistently replicated in human trials, and the precise contribution of each mechanism remains an open question.
Clinical trial data on semaglutide and body weight
The STEP clinical trial program provides the most comprehensive human data on semaglutide for weight management. STEP 1, published in 2021 by Wilding and colleagues, enrolled 1,961 adults with obesity or overweight plus at least one weight-related comorbidity. Participants receiving semaglutide 2.4 mg weekly lost an average of 15.3 kg, compared with 2.6 kg in the placebo group. STEP 4, a 2022 trial by Rubino and colleagues in JAMA, tested withdrawal of semaglutide after 20 weeks of treatment. Those who continued semaglutide lost an additional 7.9 percent of body weight, while those switched to placebo regained 6.9 percent. That rebound effect underscores the chronic nature of obesity as a condition requiring ongoing therapy.
Safety data from the STEP program highlighted gastrointestinal adverse events as the most common reason for discontinuation. Nausea, vomiting, diarrhoea, and constipation were reported in 30 to 50 percent of semaglutide-treated participants, depending on the trial. Most events were mild to moderate and occurred during dose escalation. A 2023 meta-analysis by Lin and colleagues in Obesity Reviews pooled data from 12 randomised controlled trials and found no increase in serious adverse events with semaglutide compared with placebo, though the authors noted that rare events such as pancreatitis and gallbladder disease require longer surveillance. The same analysis confirmed a small but significant increase in heart rate, averaging 2 to 3 beats per minute.
Semaglutide compared with other GLP-1 receptor agonists
Semaglutide is not the only GLP-1 RA studied for weight loss, but it has shown the largest effect size in head-to-head trials. Liraglutide 3.0 mg, approved for weight management in 2014, produces mean weight loss of 8 to 10 percent. A 2020 trial by O'Neil and colleagues in The Lancet compared semaglutide 2.4 mg with liraglutide 3.0 mg and placebo. Semaglutide led to 15.8 percent weight loss, liraglutide to 6.4 percent, and placebo to 1.9 percent. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown even greater weight loss in trials, but it is a distinct molecule with a different receptor profile. For beginners, understanding that semaglutide is one member of a broader class helps contextualise its effects and side effects.
Dosing schedules also differ across agents. Semaglutide is administered once weekly via subcutaneous injection, while liraglutide requires daily injection. Oral semaglutide exists for diabetes but has not been approved for weight management at the same dose. The once-weekly schedule improves adherence, which is a major challenge in long-term obesity treatment. However, injection technique and storage requirements can be barriers for some users. Semaglutide must be refrigerated until first use and then kept at room temperature for up to 56 days, depending on the formulation. Those practical details are rarely discussed in media coverage but matter for real-world use.
Practical considerations for research and clinical use
Semaglutide is available only by prescription in most countries and is not approved for casual or cosmetic weight loss. In the United States, the FDA approved semaglutide 2.4 mg under the brand name Wegovy in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The same molecule at lower doses is sold as Ozempic for type 2 diabetes. Off-label prescribing of Ozempic for weight loss became widespread after social media attention, leading to shortages for diabetic patients. Regulatory agencies in several countries issued warnings about compounded semaglutide, which may contain impurities or incorrect doses. A 2023 FDA warning letter to a compounding pharmacy cited failure to meet sterility standards for semaglutide products.
For researchers and clinicians, the key practical points are dose titration, monitoring, and patient selection. Semaglutide is started at 0.25 mg weekly and increased every four weeks to a maintenance dose of 2.4 mg. The titration period reduces gastrointestinal side effects but requires patience. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use semaglutide, based on rodent studies showing thyroid C-cell tumours. Those findings have not been replicated in humans, but the contraindication remains in labelling. Pancreatitis and gallbladder disease are also listed as warnings, though causal links are not firmly established.
Open questions and unresolved issues
Despite extensive trial data, several questions about semaglutide remain unanswered. Long-term safety beyond five years is unknown, as the longest published follow-up is approximately two years. Weight regain after discontinuation is nearly universal, raising questions about the optimal duration of therapy. Cost and insurance coverage create significant access barriers, especially in the United States where list prices exceed $1,000 per month. The cardiovascular outcomes trial SELECT, published in 2023 by Lincoff and colleagues in the New England Journal of Medicine, showed a 20 percent reduction in major adverse cardiovascular events with semaglutide 2.4 mg in overweight or obese patients with established cardiovascular disease. That finding may shift the risk-benefit calculus for many patients, but it also raises new questions about mechanisms independent of weight loss.
Another open question concerns the role of GLP-1 receptor agonists in combination with other peptides. Compounds such as BPC-157, GHK-Cu, and ipamorelin are sometimes discussed in online forums as adjuncts to semaglutide, but no peer-reviewed human trials support such combinations. BPC-157 is a synthetic peptide derived from a gastric protein, studied in animal models for tissue healing. GHK-Cu is a copper-binding peptide with in vitro evidence of collagen stimulation. Ipamorelin and GHRP-6 are growth hormone secretagogues that have been investigated for growth hormone deficiency but not for weight management. Cerebrolysin, a mixture of neuropeptides, has been studied for cognitive disorders. None of these compounds has been evaluated in combination with semaglutide in humans, and their safety profiles when used together are unknown. Researchers should treat such combinations as experimental and unproven.
The regulatory landscape for semaglutide continues to evolve. In 2024, the FDA updated its compounding guidance to clarify that semaglutide is not eligible for bulk compounding when the approved product is available. Several state pharmacy boards have issued similar restrictions. The World Health Organization added semaglutide to its list of essential medicines for diabetes in 2023, but not for obesity. Those regulatory actions reflect the tension between high demand and limited evidence for long-term use. For beginners, the most important lesson is that semaglutide is a prescription medication with a defined indication, not a research chemical or a lifestyle supplement.
Common questions
Is semaglutide the same as Ozempic or Wegovy?
Ozempic and Wegovy are brand names for semaglutide at different doses and indications. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly. The active molecule is identical, but the delivery devices and approved uses differ. Off-label use of Ozempic for weight loss is common but not formally approved. Compounded semaglutide products are not FDA-approved and may differ in purity or potency.
How quickly does semaglutide start working for appetite control?
Appetite suppression can begin within days of the first injection, but meaningful weight loss typically takes weeks to months. In the STEP 1 trial, weight loss was gradual and continued through week 68. Most participants lost 5 percent of body weight by week 12 and 10 percent by week 20. The full effect requires reaching the maintenance dose of 2.4 mg, which takes 16 to 20 weeks with standard titration. Some people respond more quickly, while others require the full dose before noticing changes in hunger or satiety.
Can semaglutide be used with other peptides like BPC-157 or ipamorelin?
No human clinical trials have evaluated semaglutide in combination with BPC-157, GHK-Cu, ipamorelin, GHRP-6, or Cerebrolysin. Those compounds have different mechanisms and are not approved for weight management. Combining them with semaglutide could alter gastrointestinal motility, glucose metabolism, or growth hormone signalling in unpredictable ways. Researchers investigating such combinations should proceed with caution and report adverse events. Patients should not assume that peptides sold as research chemicals are safe to combine with prescription medications.
What happens when semaglutide is stopped?
Weight regain is common after semaglutide discontinuation. In the STEP 4 trial, participants who switched to placebo regained 6.9 percent of body weight over 48 weeks, while those who continued semaglutide lost an additional 7.9 percent. Appetite returns to baseline, and gastric emptying normalises. Some patients maintain weight loss with lifestyle changes alone, but most do not. The decision to stop semaglutide should be made with a clinician, and a plan for weight maintenance should be in place before discontinuation.
Is semaglutide safe for long-term use?
The longest published follow-up for semaglutide 2.4 mg is approximately two years from the STEP 5 trial. No new safety signals emerged in that period, but rare events such as thyroid C-cell tumours, pancreatitis, and gallbladder disease require longer surveillance. The SELECT trial followed patients for a median of 39.8 months and found no increase in serious adverse events compared with placebo, though gallbladder-related events were more common with semaglutide. Long-term safety beyond five years remains unknown. Ongoing post-marketing surveillance and registry studies will provide additional data.
References to off-label or research-only use describe what has been reported in the scientific literature, not what is recommended.